MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25159109.
- Also identified by DOI 10.1002/adma.201402752.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mesoporous silica nanoparticles functionalized with peptides are developed for sequential drug delivery. The RGD peptide is used for vasculature/cell membrane targeting and the TAT peptide for nuclear targeting. Using this delivery strategy, a tumor in a murine xenograft model is successfully regressed.
Medical subject headings
- Antineoplastic Agents
- Blood Vessels
- Cell Nucleus
- Drug Carriers
- Nanoparticles
- Silicon Dioxide